checkAd

     109  0 Kommentare Evolv Technology Reports Record First Quarter Financial Results

    Evolv Technology (NASDAQ: EVLV), the leader in AI-based weapons detection security screening, today announced financial results for the quarter ended March 31, 2023 and raised its business outlook for 2023.

    Results for the First Quarter of 2023

    Total revenue for the first quarter of 2023 was $18.6 million, an increase of 113% compared to $8.7 million for the first quarter of 2022. Annual Recurring Revenue (“ARR”)1 was $42.0 million at the end of first quarter of 2023, an increase of 153% compared to $16.6 million at the end of the first quarter of 2022. Net loss for the first quarter of 2023 was $(28.6) million, or $(0.20) per basic and diluted share, compared to net loss of $(13.8) million, or $(0.10) per basic and diluted share, in the first quarter of 2022. Adjusted earnings (loss)3 for the first quarter of 2023 was $(16.9) million, or $(0.12) per diluted share, compared to adjusted earnings (loss)3 of $(18.5) million, or $(0.13) per diluted share, for the first quarter of 2022. Adjusted EBITDA3 for the first quarter of 2023 was $(15.4) million compared to $(17.3) million in the first quarter of 2022. Cash and cash equivalents as of March 31, 2023 was $182 million which reflected the Company's decision to pay off its $30 million debt facility during the first quarter of 2023. The Company had no debt as of March 31, 2023.

    The following table summarizes the breakdown of recurring and non-recurring revenue4 during each quarter:

     

    Three Months Ended
    March 31,

     

    2023

     

    2022

     

    % Change

    Recurring revenue

    $

    9,075

     

    $

    3,159

     

    187

    %

    Non-recurring revenue

     

    9,506

     

     

    5,551

     

    71

    %

    Total revenue

    $

    18,581

     

    $

    8,710

     

    113

    %

    The following table summarizes operating cash flows during each quarter:

     

    Three Months Ended
    March 31,

     

    2023

     

    2022

    Net loss

    $

    (28,609

    )

     

    $

    (13,801

    )

    Non-cash (income) expense

     

    14,005

     

     

     

    (5,126

    )

    Changes in operating assets and liabilities

     

    11,170

     

     

     

    (10,503

    )

    Net cash used in operating activities

    $

    (3,434

    )

     

    $

    (29,430

    )

    Company Raises Outlook for 2023

    The Company today commented on its business outlook for 2023. The Company's outlook is based on the current indications for its business, which may change at any time.

     

     

    2023 Business Outlook

    Estimate (In millions)

     

    Issued March 1, 2023

     

    Issued May 10, 2023

    Total Revenue

     

    $55-$60

     

    $60-$65

    Annual Recurring Revenue1 (ARR) at 12/31/23

     

    $65-$70

     

    $67-$71

    Adjusted Gross Margin3

     

    30%-35%

     

    35%-40%

    Adjusted EBITDA3

     

    ($55-$60)

     

    ($53-$58)

    Company to Host Live Conference Call and Webcast

    The Company’s management team plans to host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss the financial results as well as management’s outlook for the business and other matters. The conference call may be accessed in the United States by dialing +1.877.692.8955 and using access code 825879. The conference call may be accessed outside of the United States by dialing +1.234.720.6979 and using the same access code. The conference call will be simultaneously webcast on the Company’s investor relations website, which can be accessed at http://ir.evolvtechnology.com. A replay of the conference call will be available for a period of 30 days by dialing +1.866.207.1041 or +1.402.970.0847 and using access code 9795540 or by accessing the webcast replay on the Company’s investor relations website at http://ir.evolvtechnology.com.

    About Evolv Technology

    Evolv Technology (NASDAQ: EVLV) is transforming human security to make a safer, faster, and better experience for the world’s most iconic venues and companies as well as schools, hospitals, and public spaces, using industry leading artificial intelligence (AI)-powered weapons detection and analytics. Its mission is to transform security to create a safer world to work, learn, and play. Evolv has digitally transformed the gateways in places where people gather by enabling seamless integration combined with powerful analytics and insights. Evolv’s advanced systems have scanned more than 600 million people, second only to the Department of Homeland Security’s Transportation Security Administration (TSA) in the United States. Evolv has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT) as well as the Security Industry Association (SIA) New Products and Solutions (NPS) Award in the Law Enforcement/Public Safety/Guarding Systems category. Evolv Technology, Evolv Express, Evolv Insights, and Evolv Cortex AI are registered trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions. For more information, visit https://evolvtechnology.com.

    1 We define Annual Recurring Revenue, or ARR, as subscription revenue and the recurring service revenue related to purchase subscriptions for the final month of the quarter normalized to a one-year period. Our calculation of ARR is not adjusted for the impact of any known or projected future events (such as customer cancellations, upgrades or downgrades, or price increases or decreases) that may cause any such contract not to be renewed on its existing terms. In addition, the amount of actual revenue that we recognize over any 12-month period is likely to differ from ARR at the beginning of that period, sometimes significantly. This may occur due to new bookings, cancellations, upgrades, downgrades or other changes in pending renewals, as well as the effects of professional services revenue and acquisitions or divestitures. As a result, ARR should be viewed independently of, and not as a substitute for or forecast of, revenue and deferred revenue. Our calculation of ARR may differ from similarly titled metrics presented by other companies.

    2 We define Remaining Performance Obligation, or RPO, as estimated revenues expected to be recognized in the future related to performance obligations that are unsatisfied or partially satisfied as of the end of the quarter.

    3 Non-GAAP Financial Measures In this press release, the Company’s adjusted operating expenses, adjusted gross profit (loss), adjusted gross margin, adjusted operating income (loss), adjusted EBITDA, adjusted earnings (loss), and adjusted earnings per share-diluted are not presented in accordance with generally accepted accounting principles (GAAP) and are not intended to be used in lieu of GAAP presentations of results of operations. Adjusted gross profit and adjusted gross margin exclude one-time items including stock-based compensation expense which management believes provides a more meaningful representation of contribution margin. Adjusted operating expenses is defined as operating expenses less one-time items including stock-based compensation expense, restructuring expenses, and loss on impairment of lease equipment which management believes provides a more meaningful representation of on-going operating expense levels. Adjusted EBITDA is defined as net income (loss) plus depreciation and amortization, share-based compensation, and certain other one-time expenses. Adjusted earnings (loss) is defined as net income (loss) plus stock-based compensation, change in fair value of derivative liability, change in fair value of contingent earn-out liability, change in fair value of contingently issuable common stock liability, change in fair value of public warrant liability, change in fair value of common stock warrant liability, restructuring expenses, loss on impairment of lease equipment, and certain other one-time expenses. Management presents non-GAAP financial measures because it considers them to be important supplemental measures of performance. Management uses non-GAAP financial measures for planning purposes, including analysis of the Company's performance against prior periods, the preparation of operating budgets and to determine appropriate levels of operating and capital investments. Management also believes non-GAAP financial measures provide additional insight for analysts and investors in evaluating the Company's financial and operational performance. However, non-GAAP financial measures have limitations as an analytical tool and are not intended to be an alternative to financial measures prepared in accordance with GAAP. We intend to provide non-GAAP financial measures as part of our future earnings discussions and, therefore, the inclusion of non-GAAP financial measures will provide consistency in our financial reporting. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures included in this press release. The Company is unable to provide a reconciliation of Adjusted Gross Margin to GAAP Gross Margin and non-GAAP Adjusted EBITDA to Net Income (Loss), each measure's most directly comparable GAAP financial measure, on a forward-looking basis without unreasonable effort, because items that impact these GAAP financial measures are not within the Company’s control and/or cannot be reasonably predicted. These items may include, but are not limited to, predicting forward-looking share-based compensation, changes in the fair value of derivative liabilities, changes in the fair value of contingent earn out liabilities, changes in the fair value of contingently issuable common stock liabilities and changes in fair value of public warrant liabilities. Such information may have a significant, and potentially unpredictable, impact on the Company’s future financial results.

    4 Recurring revenue includes the recurring portion of revenue associated with pure subscription contracts and hardware purchase subscription contracts. Non-recurring revenue includes revenue that is one-time in nature, such as product revenue, shipping revenue, and revenue from installation, training, and professional services.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical facts, including without limitation statements regarding our ability to meet our 2023 annual guidance for revenue, ARR, adjusted gross margin, adjusted EBITDA, as well as our estimates for cash and cash equivalents for fiscal year 2023. Words such as “believe” “may,” “will,” “expect,” “should,” “could,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “project,” “plan,” “target,” “is/are likely to” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: expectations regarding the Company’s strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures; the Company’s history of losses and lack of profitability; the Company’s reliance on third party contract manufacturing and a global supply chain; the rate of innovation required to maintain competitiveness in the markets in which the Company competes; the loss of designation of the Evolv Express system as a Qualified Anti-Terrorism Technology under the Homeland Security SAFETY Act; the ability for the Company to obtain, maintain, protect and enforce the Company’s intellectual property rights and use of “open source” software; the concentration of the Company’s revenues on a single solution; the Company’s ability to timely design, produce and launch its solutions, the Company’s ability to invest in growth initiatives and pursue acquisition opportunities; the limited liquidity and trading of the Company’s securities; risks related to existing and changing tax laws; geopolitical risk and changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; operational risk; the impact of fluctuating general economic and market conditions; the need for additional capital to support business growth, which might not be available on acceptable terms, if at all; risks related to our indebtedness; and litigation and regulatory enforcement risks, including the diversion of management time and attention and the additional costs and demands on resources, the Company’s ability to identify and implement digital advances in its technology. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission ("SEC") on March 24, 2023 as may be updated from time to time in other filings we make with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.

    These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

     

    EVOLV TECHNOLOGY

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (In thousands, except share and per share data)

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    2023

     

    2022

    Revenue:

     

     

     

    Product revenue

    $

    8,754

     

     

    $

    5,194

     

    Subscription revenue

     

    6,466

     

     

     

    3,004

     

    Service revenue

     

    3,361

     

     

     

    512

     

    Total revenue

     

    18,581

     

     

     

    8,710

     

    Cost of revenue:

     

     

     

    Cost of product revenue

     

    10,578

     

     

     

    5,206

     

    Cost of subscription revenue

     

    2,351

     

     

     

    1,542

     

    Cost of service revenue

     

    887

     

     

     

    1,065

     

    Total cost of revenue

     

    13,816

     

     

     

    7,813

     

    Gross profit

     

    4,765

     

     

     

    897

     

    Operating expenses:

     

     

     

    Research and development

     

    5,389

     

     

     

    4,175

     

    Sales and marketing

     

    12,804

     

     

     

    9,672

     

    General and administrative

     

    8,926

     

     

     

    10,817

     

    Loss from impairment of property and equipment

     

    137

     

     

     

    96

     

    Total operating expenses

     

    27,256

     

     

     

    24,760

     

    Loss from operations

     

    (22,491

    )

     

     

    (23,863

    )

    Other income (expense), net:

     

     

     

    Interest expense

     

    (654

    )

     

     

    (142

    )

    Interest income

     

    953

     

     

     

    68

     

    Other expense, net

     

    19

     

     

     

     

    Loss on extinguishment of debt

     

    (626

    )

     

     

     

    Change in fair value of contingent earn-out liability

     

    (3,318

    )

     

     

    3,078

     

    Change in fair value of contingently issuable common stock liability

     

    (742

    )

     

     

    1,472

     

    Change in fair value of public warrant liability

     

    (1,750

    )

     

     

    5,586

     

    Total other income (expense), net

    (6,118

    )

     

    10,062

     

    Net loss

    $

    (28,609

    )

     

    $

    (13,801

    )

     

     

     

     

    Weighted average common shares outstanding – basic and diluted

     

    146,433,378

     

     

     

    142,878,406

     

    Net loss per share - basic and diluted

    $

    (0.20

    )

     

    $

    (0.10

    )

     

     

     

     

    Net loss

    $

    (28,609

    )

     

    $

    (13,801

    )

    Other comprehensive income (loss)

     

     

     

    Cumulative translation adjustment

     

    (16

    )

     

     

     

    Total other comprehensive loss

     

    (16

    )

     

     

     

    Total comprehensive loss

    $

    (28,625

    )

     

    $

    (13,801

    )

     

    EVOLV TECHNOLOGY

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except share and per share data)

    (Unaudited)

     

     

    March 31, 2023

     

    December 31,
    2022

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    180,996

     

     

    $

    229,783

     

    Restricted cash

     

    1,000

     

     

     

     

    Accounts receivable, net

     

    23,156

     

     

     

    31,920

     

    Inventory

     

    8,816

     

     

     

    10,257

     

    Current portion of contract assets

     

    3,265

     

     

     

    2,852

     

    Current portion of commission asset

     

    3,293

     

     

     

    3,384

     

    Prepaid expenses and other current assets

     

    14,413

     

     

     

    14,388

     

    Total current assets

     

    234,939

     

     

     

    292,584

     

    Restricted cash, noncurrent

     

    275

     

     

     

    275

     

    Contract assets, noncurrent

     

    715

     

     

     

    1,386

     

    Commission asset, noncurrent

     

    6,390

     

     

     

    5,655

     

    Property and equipment, net

     

    59,789

     

     

     

    44,707

     

    Operating lease right-of-use assets

     

    1,459

     

     

     

    1,673

     

    Other assets

     

    1,965

     

     

     

    1,835

     

    Total assets

    $

    305,532

     

     

    $

    348,115

     

     

     

     

     

    Liabilities and Stockholders’ Equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    19,192

     

     

    $

    18,194

     

    Accrued expenses and other current liabilities

     

    6,477

     

     

     

    11,545

     

    Current portion of deferred revenue

     

    23,977

     

     

     

    18,273

     

    Current portion of long-term debt

     

     

     

     

    10,000

     

    Current portion of operating lease liabilities

     

    1,122

     

     

     

    1,114

     

    Total current liabilities

     

    50,768

     

     

     

    59,126

     

    Deferred revenue, noncurrent

     

    20,748

     

     

     

    17,695

     

    Long-term debt, noncurrent

     

     

     

     

    19,683

     

    Operating lease liabilities, noncurrent

     

    630

     

     

     

    892

     

    Contingent earn-out liability

     

    17,536

     

     

     

    14,218

     

    Contingently issuable common stock liability

     

    4,134

     

     

     

    3,392

     

    Public warrant liability

     

    7,874

     

     

     

    6,124

     

    Total liabilities

     

    101,690

     

     

     

    121,130

     

     

     

     

     

    Stockholders’ equity:

     

     

     

    Preferred stock, $0.0001 par value; 100,000,000 authorized at March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022

     

     

     

     

     

    Common stock, $0.0001 par value; 1,100,000,000 shares authorized at March 31, 2023 and December 31, 2022; 147,977,034 and 145,204,974 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively

     

    15

     

     

     

    15

     

    Additional paid-in capital

     

    424,672

     

     

     

    419,190

     

    Accumulated other comprehensive loss

     

    (26

    )

     

     

    (10

    )

    Accumulated deficit

     

    (220,819

    )

     

     

    (192,210

    )

    Stockholders’ equity

     

    203,842

     

     

     

    226,985

     

    Total liabilities and stockholders’ equity

    $

    305,532

     

     

    $

    348,115

     

     

    EVOLV TECHNOLOGY

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In thousands)

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    2023

     

    2022

    Cash flows from operating activities:

     

     

     

    Net loss

    $

    (28,609

    )

     

    $

    (13,801

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Depreciation and amortization

     

    1,815

     

     

     

    1,086

     

    Write-off of inventory and change in inventory reserve

     

    214

     

     

     

    324

     

    Adjustment to property and equipment for sales type leases

     

     

     

     

    (625

    )

    Loss from impairment of property and equipment

     

    137

     

     

     

    96

     

    Stock-based compensation

     

    5,043

     

     

     

    3,927

     

    Non-cash interest expense

     

    22

     

     

     

    5

     

    Non-cash lease expense

     

    214

     

     

     

    197

     

    Change in allowance for expected credit losses

     

    124

     

     

     

     

    Loss on extinguishment of debt

     

    626

     

     

     

     

    Change in fair value of earn-out liability

     

    3,318

     

     

     

    (3,078

    )

    Change in fair value of contingently issuable common stock

     

    742

     

     

     

    (1,472

    )

    Change in fair value of public warrant liability

     

    1,750

     

     

     

    (5,586

    )

    Changes in operating assets and liabilities

     

     

     

    Accounts receivable

     

    8,640

     

     

     

    (2,112

    )

    Inventory

     

    1,418

     

     

     

    (1,310

    )

    Commission assets

     

    (644

    )

     

     

    (351

    )

    Contract assets

     

    258

     

     

     

    108

     

    Other assets

     

    (130

    )

     

     

    141

     

    Prepaid expenses and other current assets

     

    (25

    )

     

     

    (5,571

    )

    Accounts payable

     

    (2,213

    )

     

     

    (855

    )

    Deferred revenue

     

    8,757

     

     

     

    2,577

     

    Accrued expenses and other current liabilities

     

    (4,637

    )

     

     

    (2,433

    )

    Operating lease liability

     

    (254

    )

     

     

    (697

    )

    Net cash used in operating activities

     

    (3,434

    )

     

     

    (29,430

    )

    Cash flows from investing activities:

     

     

     

    Development of internal-use software

     

    (733

    )

     

     

    (728

    )

    Purchases of property and equipment

     

    (13,365

    )

     

     

    (6,689

    )

    Proceeds from sale of property and equipment

     

    60

     

     

     

     

    Net cash used in investing activities

     

    (14,038

    )

     

     

    (7,417

    )

    Cash flows from financing activities:

     

     

     

    Proceeds from exercise of stock options

     

    33

     

     

     

    227

     

    Proceeds from long-term debt

     

    1,876

     

     

     

     

    Repayment of principal on long-term debt

     

    (31,876

    )

     

     

     

    Payment of debt issuance costs and prepayment penalty

     

    (332

    )

     

     

     

    Net cash provided by (used in) financing activities

     

    (30,299

    )

     

     

    227

     

    Effect of exchange rate changes on cash and cash equivalents

     

    (16

    )

     

     

     

    Net increase (decrease) in cash, cash equivalents and restricted cash

     

    (47,787

    )

     

     

    (36,620

    )

    Cash, cash equivalents and restricted cash

     

     

     

    Cash, cash equivalents and restricted cash at beginning of period

     

    230,058

     

     

     

    308,167

     

    Cash, cash equivalents and restricted cash at end of period

    $

    182,271

     

     

    $

    271,547

     

    EVOLV TECHNOLOGY
    REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS
    (In thousands)
    (Unaudited)

    In preparing the condensed consolidated financial statements as of and for the three and six months ended June 30, 2022, the Company identified various errors in its previously issued financial statements. The identified errors impacted the Company's previously issued quarterly financial statements for the three months ended March 31, 2022, and accordingly the Company has made adjustments to the prior period amounts presented herein. Additionally, the Company has made adjustments to correct for other previously identified immaterial errors. The Company evaluated the errors and determined that the related impacts were not material to any previously issued annual or interim financial statements. The impact of the revisions to the quarterly period ending March 31, 2022 is presented as follows (in thousands):

     

    Three Months Ended
    March 31, 2022

     

    As Previously Reported

     

    Adjustment

     

    As Revised

    Revenue:

     

     

     

     

     

    Product revenue

    $

    5,194

     

     

    $

     

     

    $

    5,194

     

    Subscription revenue

     

    3,020

     

     

     

    (16

    )

     

     

    3,004

     

    Service revenue

     

    501

     

     

     

    11

     

     

     

    512

     

    Total revenue

     

    8,715

     

     

     

    (5

    )

     

     

    8,710

     

    Cost of revenue:

     

     

     

     

     

    Cost of product revenue

     

    5,576

     

     

     

    (370

    )

     

     

    5,206

     

    Cost of subscription revenue

     

    1,065

     

     

     

    477

     

     

     

    1,542

     

    Cost of service revenue

     

    448

     

     

     

    617

     

     

     

    1,065

     

    Total cost of revenue

     

    7,089

     

     

     

    724

     

     

     

    7,813

     

    Gross profit

     

    1,626

     

     

     

    (729

    )

     

     

    897

     

    Operating expenses:

     

     

     

     

     

    Research and development

     

    4,286

     

     

     

    (111

    )

     

     

    4,175

     

    Sales and marketing expense

     

    12,053

     

     

     

    (2,381

    )

     

     

    9,672

     

    General and administrative

     

    11,093

     

     

     

    (276

    )

     

     

    10,817

     

    Loss from impairment of property and equipment

     

    96

     

     

     

     

     

     

    96

     

    Total operating expenses

     

    27,528

     

     

     

    (2,768

    )

     

     

    24,760

     

    Loss from operations

     

    (25,902

    )

     

     

    2,039

     

     

     

    (23,863

    )

    Other income (expense), net:

     

     

     

     

     

    Interest expense

     

    (142

    )

     

     

     

     

     

    (142

    )

    Interest income

     

    209

     

     

     

    (141

    )

     

     

    68

     

    Change in fair value of contingent earn-out liability

     

    4,226

     

     

     

    (1,148

    )

     

     

    3,078

     

    Change in fair value of contingently issuable common stock liability

     

    1,472

     

     

     

     

     

     

    1,472

     

    Change in fair value of public warrant liability

     

    5,586

     

     

     

     

     

     

    5,586

     

    Total other income (expense), net

     

    11,351

     

     

     

    (1,289

    )

     

     

    10,062

     

    Net loss

    $

    (14,551

    )

     

    $

    750

     

     

    $

    (13,801

    )

     

     

     

     

     

     

    Weighted average common shares outstanding - basic and diluted

     

    142,878,406

     

     

     

     

     

     

    142,878,406

     

    Net loss per share - basic and diluted

    $

    (0.10

    )

     

    $

     

     

    $

    (0.10

    )

     

     

    Three Months Ended
    March 31, 2022

     

    As Previously Reported

    Adjustment

    As Revised

    Cash flows from operating activities:

     

     

     

    Net loss

    $

    (14,551

    )

    $

    750

     

    $

    (13,801

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Depreciation and amortization

     

    948

     

     

    138

     

     

    1,086

     

    Write-off of inventory

     

    324

     

     

     

     

    324

     

    Adjustment to property and equipment for sales type leases

     

    (321

    )

     

    (304

    )

     

    (625

    )

    Loss from impairment of property and equipment

     

    96

     

     

     

     

    96

     

    Stock-based compensation

     

    5,190

     

     

    (1,263

    )

     

    3,927

     

    Non-cash interest expense

     

    5

     

     

     

     

    5

     

    Non-cash lease expense

     

    197

     

     

     

     

    197

     

    Change in fair value of earn-out liability

     

    (4,226

    )

     

    1,148

     

     

    (3,078

    )

    Change in fair value of contingently issuable common stock

     

    (1,472

    )

     

     

     

    (1,472

    )

    Change in fair value of public warrant liability

     

    (5,586

    )

     

     

     

    (5,586

    )

    Changes in operating assets and liabilities

     

     

     

    Accounts receivable

     

    (2,112

    )

     

     

     

    (2,112

    )

    Inventory

     

    (6,985

    )

     

    5,675

     

     

    (1,310

    )

    Commission assets

     

    (351

    )

     

     

     

    (351

    )

    Contract assets

     

    108

     

     

     

     

    108

     

    Other assets

     

     

     

    141

     

     

    141

     

    Prepaid expenses and other current assets

     

    (5,280

    )

     

    (291

    )

     

    (5,571

    )

    Accounts payable

     

    (1,867

    )

     

    1,012

     

     

    (855

    )

    Deferred revenue

     

    2,778

     

     

    (201

    )

     

    2,577

     

    Deferred rent

     

    (468

    )

     

    468

     

     

     

    Accrued expenses and other current liabilities

     

    (2,065

    )

     

    (368

    )

     

    (2,433

    )

    Operating lease liability

     

    (229

    )

     

    (468

    )

     

    (697

    )

    Net cash used in operating activities

     

    (35,867

    )

     

    6,437

     

     

    (29,430

    )

    Cash flows from investing activities:

     

     

     

    Development of internal-use software

     

    (646

    )

     

    (82

    )

     

    (728

    )

    Purchases of property and equipment

     

    (323

    )

     

    (6,366

    )

     

    (6,689

    )

    Net cash used in investing activities

     

    (969

    )

     

    (6,448

    )

     

    (7,417

    )

    Cash flows from financing activities:

     

     

     

    Proceeds from exercise of stock options

     

    216

     

     

    11

     

     

    227

     

    Net cash provided by financing activities

     

    216

     

     

    11

     

     

    227

     

    Net increase (decrease) in cash, cash equivalents and restricted cash

     

    (36,620

    )

     

     

     

    (36,620

    )

    Cash, cash equivalents and restricted cash

     

     

     

    Cash, cash equivalents and restricted cash at beginning of period

     

    308,167

     

     

     

     

    308,167

     

    Cash, cash equivalents and restricted cash at end of period

    $

    271,547

     

    $

     

    $

    271,547

     

    Supplemental disclosure of non-cash activities

     

     

     

    Transfer of inventory to property and equipment

    $

    4,620

     

    $

    (4,620

    )

    $

     

    Capital expenditures incurred but not yet paid

     

    1,693

     

     

    698

     

     

    2,391

     

     

    EVOLV TECHNOLOGY

    SUMMARY OF KEY OPERATING STATISTICS

    (Unaudited)

     

     

    Three Months Ended or as of,

    ($ in thousands)

     

    March 31,
    2022

     

    June 30,
    2022

     

    September 30,
    2022

     

    December 31,
    2022

     

    March 31,
    2023

    New customers

     

     

    44

     

     

    53

     

     

    92

     

     

    106

     

     

    61

    Annual recurring revenue

     

    $

    16,641

     

    $

    20,865

     

    $

    28,741

     

    $

    34,120

     

    $

    42,021

    Recurring revenue

     

    $

    3,159

     

    $

    4,604

     

    $

    6,221

     

    $

    7,388

     

    $

    9,075

    Remaining performance obligation

     

    $

    63,750

     

    $

    80,978

     

    $

    109,407

     

    $

    144,561

     

    $

    161,813

    Net additions

     

     

    207

     

     

    237

     

     

    545

     

     

    575

     

     

    520

    Ending deployed units

     

     

    910

     

     

    1,147

     

     

    1,692

     

     

    2,267

     

     

    2,787

     

    EVOLV TECHNOLOGY

    RECONCILIATION OF GAAP OPERATING EXPENSES TO ADJUSTED OPERATING EXPENSES

    (In thousands)

    (Unaudited)

     

     

    Three Months Ended,

     

     

    March 31,
    2022

     

    June 30,
    2022

     

    September 30,
    2022

     

    December 31,
    2022

     

    March 31,
    2023

    Operating expenses, GAAP

     

    $

    24,760

     

     

    $

    25,835

     

     

    $

    26,827

     

     

    $

    26,868

     

     

    $

    27,256

     

    Stock-based compensation

     

     

    (3,819

    )

     

     

    (4,781

    )

     

     

    (6,298

    )

     

     

    (6,771

    )

     

     

    (4,898

    )

    Restructuring expenses

     

     

    (324

    )

     

     

    13

     

     

     

     

     

     

     

     

     

     

    Loss on impairment of lease equipment

     

     

    (96

    )

     

     

    (316

    )

     

     

    (626

    )

     

     

    (123

    )

     

     

    (137

    )

    Other one-time expenses

     

     

    (1,107

    )

     

     

    (2,298

    )

     

     

    (69

    )

     

     

    (41

    )

     

     

    (53

    )

    Adjusted Operating Expenses

     

    $

    19,414

     

     

    $

    18,453

     

     

    $

    19,834

     

     

    $

    19,933

     

     

    $

    22,168

     

     

    EVOLV TECHNOLOGY

    RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED GROSS PROFIT, GAAP GROSS MARGIN TO ADJUSTED GROSS MARGIN AND GAAP OPERATING INCOME (LOSS) TO ADJUSTED OPERATING INCOME (LOSS)

    (In thousands)

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    2023

     

    2022

    Revenue

    $

    18,581

     

     

    $

    8,710

     

    Cost of revenue

     

    13,816

     

     

     

    7,813

     

    Gross Profit, GAAP

     

    4,765

     

     

     

    897

     

    Stock-based compensation

     

    145

     

     

     

    108

     

    Amortization of capitalized stock-based compensation

     

    10

     

     

     

    3

     

    Adjusted Gross Profit

    $

    4,920

     

     

    $

    1,008

     

     

     

     

     

    Gross Margin %

     

    25.6

    %

     

     

    10.3

    %

    Adjusted Gross Margin %

     

    26.5

    %

     

     

    11.6

    %

     

    Three Months Ended
    March 31,

     

    2023

     

    2022

    Operating income (loss), GAAP

    $

    (22,491

    )

     

    $

    (23,863

    )

    Stock-based compensation

     

    5,043

     

     

     

    3,927

     

    Amortization of capitalized stock-based compensation

     

    10

     

     

     

    3

     

    Restructuring expenses

     

     

     

     

    324

     

    Loss on impairment of lease equipment

     

    137

     

     

     

    96

     

    Other one-time expenses

     

    53

     

     

     

    1,107

     

    Adjusted Operating Income (Loss)

    $

    (17,248

    )

     

    $

    (18,406

    )

     

    EVOLV TECHNOLOGY

    RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA

    (In thousands)

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    2023

     

    2022

    Net loss

    $

    (28,609

    )

     

    $

    (13,801

    )

    Depreciation & amortization

     

    1,815

     

     

     

    1,086

     

    Stock-based compensation

     

    5,043

     

     

     

    3,927

     

    Interest expense (income)

     

    (299

    )

     

     

    74

     

    Loss on disposal of property & equipment

     

     

     

     

     

    Loss on extinguishment of debt

     

    626

     

     

     

     

    Change in fair value of contingent earn-out liability

     

    3,318

     

     

     

    (3,078

    )

    Change in fair value of contingently issuable common stock liability

     

    742

     

     

     

    (1,472

    )

    Change in fair value of public warrant liability

     

    1,750

     

     

     

    (5,586

    )

    Restructuring expenses

     

     

     

     

    324

     

    Loss on impairment of lease equipment

     

    137

     

     

     

    96

     

    Other one-time expenses

     

    53

     

     

     

    1,107

     

    Adjusted EBITDA

    $

    (15,424

    )

     

    $

    (17,323

    )

     

    EVOLV TECHNOLOGY

    RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EARNINGS (LOSS)

    (In thousands, except share and per share data)

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    2023

     

    2022

    Net loss

    $

    (28,609

    )

     

    $

    (13,801

    )

    Stock-based compensation

     

    5,043

     

     

     

    3,927

     

    Amortization of capitalized stock-based compensation

     

    10

     

     

     

    3

     

    Loss on extinguishment of debt

     

    626

     

     

     

     

    Change in fair value of contingent earn-out liability

     

    3,318

     

     

     

    (3,078

    )

    Change in fair value of contingently issuable common stock liability

     

    742

     

     

     

    (1,472

    )

    Change in fair value of public warrant liability

     

    1,750

     

     

     

    (5,586

    )

    Restructuring expenses

     

     

     

     

    324

     

    Loss on impairment of lease equipment

     

    137

     

     

     

    96

     

    Other one-time expenses

     

    53

     

     

     

    1,107

     

    Adjusted Earnings (Loss)

    $

    (16,930

    )

     

    $

    (18,480

    )

     

     

     

     

    Weighted average common shares outstanding – diluted

     

    146,433,378

     

     

     

    142,878,406

     

     

     

     

     

    Adjusted Earnings (Loss) Per Share – diluted

    $

    (0.12

    )

     

    $

    (0.13

    )

     


    The Evolv Technologies Holdings Registered (A) Stock at the time of publication of the news with a fall of -0,73 % to 4,06USD on Nasdaq stock exchange (10. Mai 2023, 22:00 Uhr).


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Evolv Technology Reports Record First Quarter Financial Results Evolv Technology (NASDAQ: EVLV), the leader in AI-based weapons detection security screening, today announced financial results for the quarter ended March 31, 2023 and raised its business outlook for 2023. Results for the First Quarter of 2023 …

    Artikel zu den Werten

    Schreibe Deinen Kommentar

    Disclaimer